SSG
DNA icon

Summit Securities Group’s Ginkgo Bioworks DNA Stock Holding History

Summit Securities Group’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,175
Closed -$85K – 720
2023
Q3 		$85K Buy
+1,175
New +$93.9K 0.01% 234

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Summit Securities Group's DNA Position: Q4 2023 in Review

Summit Securities Group sold out of Ginkgo Bioworks (DNA) in Q4 2023, closing a stake of 1,175 shares — an estimated $85K sold.

Summit Securities Group first reported a position in DNA in Q3 2023 and held it in 1 quarter. The position peaked at $85K in Q3 2023. 342 funds tracked by Wall St. Rank hold DNA as of Q4 2023.

  • Summit Securities Group reported no remaining Ginkgo Bioworks position as of Q4 2023 after selling out during the quarter.
  • Summit Securities Group sold 1,175 Ginkgo Bioworks shares in Q4 2023, an estimated $85K.
  • Summit Securities Group first reported a position in Ginkgo Bioworks in Q3 2023 and held it in 1 quarter.
  • Summit Securities Group's Ginkgo Bioworks position peaked at $85K in Q3 2023.
  • 342 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2023.

Based on Summit Securities Group's 13F filing for Q4 2023, filed 14 Feb 2024.